索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]董晓敏 龚勋 蔡丽萍.急性心肌梗死后左室血栓形成机制及抗栓治疗进展[J].国际心血管病杂志,2018,06:332-336.
点击复制

急性心肌梗死后左室血栓形成机制及抗栓治疗进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2018年06期
页码:
332-336
栏目:
综述
出版日期:
2019-02-01

文章信息/Info

Title:
-
作者:
董晓敏 龚勋 蔡丽萍
Author(s):
-
关键词:
左室血栓;  急性心肌梗死;  形成机制;  抗栓治疗
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2018.06.004
文献标识码:
-
摘要:
左室血栓是急性心肌梗死的重要并发症,最常出现于ST段抬高型心肌梗死。左室内膜损伤、血流缓慢、高凝状态为急性心肌梗死引起左室血栓的原因,而血栓脱落会导致栓塞事件的发生。该文介绍急性心肌梗死后左室血栓形成机制及抗栓治疗的研究进展。
Abstract:
-

参考文献/References


[1] Nihoyannopoulos P, Smith GC, Maseri A, et al. The natural history of left ventricular thrombus in myocardial infarction: a rationale in support of masterly inactivity[J]. J Am Coll Cardiol, 1989, 14(4):903-911.
[2] Chamsi-Pasha H, Barnes PC. Left ventricular thrombosis in acute transmural myocardial infarction[J]. Postgrad Med J, 1988, 64(749):188-190.
[3] Robinson AA, Jain A, Gentry M, et al. Left ventricular thrombi after STEMI in the primary PCI era: a systematic review and meta-analysis[J]. Int J Cardiol, 2016, 221:554-559.
[4] 段鹏, 陆世红, 张小勇, 等. 急性ST段抬高型心肌梗死并左室血栓形成的危险因素分析[J]. 临床心血管病杂志, 2016, 32(3):251-254.
[5] Jiang YX, Jing LD, Jia YH. Clinical characteristics and risk factors of left ventricular thrombus after acute myocardial infarction: a matched case-control study[J]. Chin Med J(Engl), 2015, 128(18):2415-2419.
[6] Weinsaft JW, Kim J, Medicherla CB, et al. Echocardiographic algorithm for post-myocardial infarction LV thrombus a gatekeeper for thrombus evaluation by delayed enhancement CMR[J]. JACC Cardiovasc Imaging, 2016, 9(5):505-515.
[7] 刘永利. 急性心肌梗死后左心室壁瘤形成机制、并发症及治疗[J]. 中国心血管病研究, 2012, 10(10):791-794.
[8] 肖铁卉, 王士雯, 陈艳明, 等. 心肌梗死后室壁瘤合并附壁血栓形成的相关因素分析[J]. 临床荟萃, 2007, 22(7):464-466.
[9] 张治平, 鄢华, 刘成伟, 等. 急性心肌梗死后室壁瘤形成与左室附壁血栓的关系[J]. 实用医学杂志, 2011, 27(24):4480-4481.
[10] Celik S, Baykan M, Erdol C, et al. C-reactive protein as a risk factor for left ventricular thrombus in patients with acute myocardial infarction[J]. Clin Cardiol, 2001, 24(9):615-619.
[11] Ebrahimi M, Fazlinezhad A, Alvandi-Azari M, et al. Long-term clinical outcomes of the left ventricular thrombus in patients with ST elevation anterior myocardial infarction[J]. ARYA Atheroscler, 2015, 11(1):1-4.
[12] Delewi R, Zijlstra F, Piek JJ. Left ventricular thrombus formation after acute myocardial infarction[J]. Heart, 2012, 98(23):1743-1749.
[13] Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction[J]. Circulation, 1994, 90(1):61-68.
[14] Yilmaz MB, Ozeke O, Akin Y, et al. Platelet aggregation in left ventricular thrombus formation after acute anterior myocardial infarction: mean platelet volume[J]. Int J Cardiol, 2003, 90(1):123-125.
[15] Lansberg MG, O'donnell MJ, Khatri PA, et al. Antithrombotic and thrombolytic therapy for ischemic stroke antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines[J]. Chest, 2012, 141(2 Suppl):e601S-e636S.
[16] American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, O'gara PT, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2013, 61(4):e78-e140.
[17] 中华医学会心血管病学分会. 2015 急性ST段抬高型心肌梗死诊断和治疗指南[J]. 中华心血管病杂志, 2015, 43(05):380-393.
[18] Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation:the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology(ESC). Eur Heart J, 2018, 39(2):119-177.
[19] Kontny F, Dale J, Abildgaard U, et al. Randomized trial of low molecular weight heparin(dalteparin)in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction:the Fragmin in Acute Myocardial Infarction(FRAMI)Study[J]. J Am Coll Cardiol, 1997, 30(4):962-969.
[20] Le May MR, Acharya S, Wells GA, et al. Prophylactic warfarin therapy after primary percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction[J]. JACC Cardiovasc Interv, 2015, 8(1 Pt B):155-162.
[21] Shavadia JS, Youngson E, Bainey KR, et al. Outcomes and prognostic impact of prophylactic oral anticoagulation in anterior ST-segment elevation myocardial infarction patients with left ventricular dysfunction[J]. J Am Heart Assoc, 2017, 6(7):e006054.
[22] Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome[J]. N Engl J Med, 2011, 365(8):699-708.
[23] Mega JL, Braunwald E, Murphy SA, et al. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial(Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction-51)[J]. J Am Coll Cardiol, 2013, 61(18):1853-1859.
[24] Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease:an international,randomised,double-blind,placebo-controlled trial[J]. Lancet, 2017, 391(10117):219-229.
[25] Driesman A, Hyder O, Lang C, et al. Incidence and predictors of left ventricular thrombus after primary percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction[J]. Clin Cardiol, 2015, 38(10):590-597.
[26] Kremer P, Fiebig R, Tilsner V, et al. Lysis of left ventricular thrombi with urokinase[J]. Circulation, 1985, 72(1):112-118.
[27] Bautista RE. Embolic stroke following thrombolytic therapy for myocardial infarction in a patient with preexisting ventricular thromb[J]. Stroke. 1995, 26(2):324-325.
[28] Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke, 2014, 45(7):2160-2236.
[29] Yassin AS, Abubakar H, Mishra T, et al. Rivaroxaban for left ventricular thrombus[J]. Am J Ther, 2018,Feb 6.[Epub ahead of print].
[30] 徐高峰. 不同剂量利伐沙班用于左心室心尖部血栓治疗的临床效果及安全性比较[J]. 中国基层医药, 2016, 23(21):3272-3275.
[31] 李秀芬, 葛振嵘, 帕尔哈提·吐尔逊. 利伐沙班与华法林治疗左心室心尖部血栓的疗效比较[J]. 中国循环杂志, 2015, 30(6):559-561.
[32] Mano Y, Koide K, Sukegawa H, et al. Successful resolution of a left ventricular thrombus with apixaban treatment following acute myocardial infarction[J]. Heart Vessels, 2016, 31(1):118-123.
[33] Berry A, Brancheau D, Zughaib M. Rapid resolution of left ventricular thrombus with apixaban therapy [J]. SAGE Open Med Case Rep, 2017, 5:1-3.
[34] Nagamoto Y, Shiomi T, Matsuura T, et al. Resolution of a left ventricular thrombus by the thrombolytic action of dabigatran[J]. Heart Vessels, 2014, 29(4):560-562.
[35] Ohashi N, Okada T, Uchida M, et al. Effects of dabigatran on the resolution of left ventricular thrombus after acute myocardial infarction[J]. Intern Med, 2015, 54(14):1761-1763.
[36] Maniwa N, Fujino M, Nakai M, et al. Anticoagulation combined with antiplatelet therapy in patients with left ventricular thrombus after first acute myocardial infarction[J]. Eur Heart J, 2018, 39(3):201-208.
[37] Angiolillo DJ, Goodman SG, Bhatt DL, et al. Antithrombolic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention. A North American perspective—2018 update[J]. Circulation, 2018, 138:527-536.

备注/Memo

备注/Memo:
作者单位:541001 桂林医学院附属医院药学部(董晓敏,龚勋); 536000 北海,广西医科大学第九附属医院药学部(蔡丽萍)
通信作者:蔡丽萍,Email:352512070@qq.com
更新日期/Last Update: 2018-11-30